DePuy Synthes tells us that implant survivorship data from the 2016 Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) confirm positive early results for its ATTUNE® Knee System.
Part of the Johnson & Johnson Family of Companies, DePuy Synthes recently touted UK registry data that supported its Attune Knee system. Hot on the heels come data from Australia that add to it and provide supporting evidence that survivorship for the ATTUNE Knee compares favorably to other cemented knee systems in its class.
In addition, recently-presented interim data on two studies suggest improved patient reported outcomes measures with the ATTUNE Knee compared to other leading knee systems.
Per the 2016 AOANJRR, in which 4,831 ATTUNE Knees are being tracked, the ATTUNE Knee estimated cumulative percent revision was 0.5% (ATTUNE Cruciate Retaining Knee) and 0.4% (ATTUNE Posterior Stabilized Knee) at one year. This compares favorably to the overall class of cemented total knee arthroplasty (TKA) at one year, which has an estimated cumulative percent revision of 1.0%.
In addition, interim results from an ongoing study of patients implanted with ATTUNE Posterior Stabilized (PS)TKA Knees showed a reduced incidence of symptomatic crepitus that was half of that compared to non-ATTUNE PS TKA Knees at a minimum of one year.
“There is a steady cadence of evidence for the ATTUNE Knee that suggests improved outcomes and functional performance” said Paul Voorhorst, Vice President of Clinical Research for DePuy Synthes Joint Reconstruction. “We are committed to ongoing monitoring of both the outcomes and economic benefits of this new technology.”
Source: DePuy Synthes